=pics[thenum]; x+=1; setTimeout('change_it2()',delay); } //--> Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that is developing novel drugs for the treatment.... About ITI | Technology & Products | Therapeutic Programs | Press Room | Career | Contact ITI 2002-2013 Intracellular Therapies, Inc. ..., the Company incorporates its CNSProfile , a state-of-the-art platform that allows ITI to choose compounds with the strongest potential to succeed in these difficult to treat diseases...

, 2008 -- Intra-Cellular Therapies, Inc., today announced additional preclinical data from its ongoing development programs for ITI-007, the Company's first-in-class dual 5HT2A... Therapies, Inc. (ITI), is a biopharmaceutical company that is developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS). Building...Read more. Press Room Press Release FOR IMMEDIATE RELEASE INTRA-CELLULAR THERAPIES ANNOUNCES THE DISCOVERY OF POTENT ANTIDEPRESSANT ACTIVITY IN ITI-007 NEW YORK, NY, APRIL 9TH...

disorders such as sleep disorders in depression, other mood disorders, Alzheimer's disease and schizophrenia. ABOUT INTRA-CELLULAR THERAPIES Intra-Cellular Therapies, Inc. (ITI...Read more. Press Room Press Release FOR IMMEDIATE RELEASE INTRA-CELLULAR THERAPIES ANNOUNCES THE RESULTS OF A PHASE I PET STUDY FOR ITI-007 FOR THE TREATMENT OF SCHIZOPHRENIA AND... OTHER PSYCHIATRIC DISORDERS Key Targets are Critical to Drug Treatment of Neuropsychiatric and Related Disorders NEW YORK, Dec. 21 /PRNewswire/ -- Intra-Cellular Therapies, Inc...

WINTER WORKSHOP ON SCHIZOPHRENIA AND BIPOLAR DISORDERS NEW YORK, NY, FEBRUARY 15TH, 2008 -- Intra-Cellular Therapies, Inc. (ITI), announced the presentation of preclinical data... of proprietary compounds and also to evaluate in-licensing opportunities. ABOUT INTRA-CELLULAR THERAPIES Intra-Cellular Therapies, Inc. (ITI), is a biopharmaceutical company that is developing... on ITI-007, its first-in-class dual 5HT2A receptor anatagonist/dopamine receptor phosphoprotein modulator (DPPM) for the treatment of schizophrenia, and ITI-002, ITIs family...